KALA PHARMACEUTICALS INC's ticker is KALA and the CUSIP is 483119103. A total of 85 filers reported holding KALA PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 7.30 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $250,000 | +13.1% | 162,134 | +0.6% | 0.00% | – |
| Q4 2021 | $221,000 | -57.5% | 161,131 | -3.4% | 0.00% | – |
| Q3 2021 | $520,000 | -46.0% | 166,749 | -8.2% | 0.00% | – |
| Q2 2021 | $963,000 | -49.8% | 181,653 | -36.2% | 0.00% | -100.0% |
| Q1 2021 | $1,918,000 | +17.9% | 284,639 | +18.7% | 0.00% | 0.0% |
| Q4 2020 | $1,627,000 | +37.4% | 239,869 | +52.0% | 0.00% | – |
| Q3 2020 | $1,184,000 | -57.2% | 157,813 | -40.1% | 0.00% | -100.0% |
| Q2 2020 | $2,767,000 | +74.6% | 263,306 | +46.0% | 0.00% | 0.0% |
| Q1 2020 | $1,585,000 | +144.6% | 180,334 | +2.7% | 0.00% | – |
| Q4 2019 | $648,000 | +72.3% | 175,623 | +77.8% | 0.00% | – |
| Q3 2019 | $376,000 | -62.0% | 98,752 | -36.3% | 0.00% | – |
| Q2 2019 | $989,000 | – | 154,914 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Athyrium Capital Management, LP | 1,333,333 | $5,073,000 | 100.00% |
| CAXTON CORP | 1,483,343 | $5,644,000 | 6.36% |
| Polaris Venture Management Co. V, L.L.C. | 1,197,032 | $4,555,000 | 2.59% |
| RA Capital Management | 4,537,478 | $17,265,000 | 1.03% |
| Orbimed Advisors | 3,447,840 | $13,119,000 | 0.25% |
| Matisse Capital | 46,500 | $177,000 | 0.22% |
| PURA VIDA INVESTMENTS, LLC | 332,831 | $1,266,000 | 0.22% |
| Sofinnova Investments, Inc. | 478,206 | $1,819,000 | 0.16% |
| HARBOURVEST PARTNERS LLC | 99,186 | $377,000 | 0.16% |
| ALGERT GLOBAL LLC | 47,195 | $180,000 | 0.07% |